• FDA Grants Accelerated Approval to Keytruda for Gastric Cancer
  • FDA OKs Opdivo as Liver Cancer Therapy for Patients Who Did Not Respond to Nexavar
  • UK’s NICE Approves Opdivo as Second-line NSCLC Treatment through Cancer Drugs Fund
  • European Commission Approves Bavencio as First Immunotherapy for Adult Metastatic Merkel Cell Carcinoma
  • Opdivo, HPV Cancer Vaccine Combo Improves Response Rates in Oropharyngeal Cancer Patients
  • Tafinlar-Mekinist Combo is Highly Effective Adjuvant Therapy for Melanoma, Researchers Say
  • Keytruda Better than Standard Treatment for Advanced Head and Neck Cancer, Keynote-040 Study Shows
  • X4P-001 and Inlyta Combo Shows Promise Against Kidney Cancer, Trial Indicates
  • Imfinzi Reduces Risk of Disease Progression in Advanced NSCLC Patients, PACIFIC Trial Shows
  • Updated Phase 3 Trial Results Continue to Favor Keytruda as Second-Line Treatment for Bladder Cancer
  • Rocapuldencel-T Improves Survival in Renal Cell Carcinoma Patients, Phase 3 Trial Suggests
  • Immuno-oncology Becoming Established as Fifth Pillar of Cancer Therapy, Analysts Say